drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Engineered TCR T-cell therapy targeting NY-ESO-1; autologous T cells modified to express a T-cell receptor recognizing NY-ESO-1 peptide–HLA complexes on tumor cells.
nci_thesaurus_concept_id
C121379
nci_thesaurus_preferred_term
Letetresgene Autoleucel
nci_thesaurus_definition
Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.
drug_mesh_term
Adoptive Immunotherapy
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transduced to express a high‑affinity TCR specific for NY‑ESO‑1/LAGE‑1 peptide–HLA complexes on tumor cells. After infusion, these TCR‑engineered T cells recognize antigen-presenting tumor cells and mediate cytotoxic killing and cytokine-driven anti-tumor responses.
drug_name
Letetresgene autoleucel
nct_id_drug_ref
NCT06113315